Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of I-Mab's Givastomig?
Givastomig is a monoclonal antibody commercialized by I-Mab, with a leading Phase I program in Gastric Cancer;Gastroesophageal (GE) Junction Carcinomas....
Givastomig by I-Mab for Solid Tumor: Likelihood of Approval
Givastomig is under clinical development by I-Mab and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Givastomig by I-Mab for Gastric Cancer: Likelihood of Approval
Givastomig is under clinical development by I-Mab and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...